CSIMarket
 
Concert Pharmaceuticals Inc   (CNCE)
Other Ticker:  
 
 
Price: $8.3700 $0.01 0.120%
Day's High: $8.55 Week Perf: -0.36 %
Day's Low: $ 8.35 30 Day Perf: -0.24 %
Volume (M): 10,733 52 Wk High: $ 0.00
Volume (M$): $ 89,837 52 Wk Avg: $0.00
Open: $8.38 52 Wk Low: $0.00



 Market Capitalization (Millions $) 416
 Shares Outstanding (Millions) 50
 Employees 107
 Revenues (TTM) (Millions $) 0
 Net Income (TTM) (Millions $) -186
 Cash Flow (TTM) (Millions $) -8
 Capital Exp. (TTM) (Millions $) 0

Concert Pharmaceuticals Inc
Concert Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company that focuses on developing innovative medicines to treat patients who are suffering from serious diseases by applying its deuterium chemistry technology. Deuterium is a naturally occurring and stable isotope of hydrogen. This technology enables the company to create new chemical entities with potential advantages across a range of therapeutic areas, including oncology, central nervous system disorders, and inflammation, among others.

The company was founded in 2006 and is headquartered in Lexington, Massachusetts. Its portfolio includes several drug candidates that are either in preclinical or clinical development phases. Their lead program, CTP-543, is an oral drug candidate for the treatment of moderate-to-severe alopecia areata (AA), an autoimmune disease that affects hair growth. It has completed Phase 2a clinical trials and has demonstrated positive results in reducing the severity of AA symptoms.

Another program in concert pharmaceuticals is the AVP-786 program focuses on treating neurologic and psychiatric conditions, such as Alzheimer's disease, schizophrenia, and bipolar disorder. It is a combination of two compounds, dextromethorphan and quinidine. The combination is designed to treat symptoms associated with these conditions by targeting the overactive N-methyl-D-aspartate (NMDA) receptors within the brain.

Concert Pharmaceuticals also has a partnership with Celgene, a subsidiary of Bristol-Myers Squibb, to develop CTP-730, a deuterium-modified version of apremilast. It is an oral medication that works by inhibiting phosphodiesterase 4 (PDE4) and reducing inflammation. The drug is currently in Phase 1 clinical trials for the treatment of moderate-to-severe psoriasis.

The company's approach to drug development is unique and innovative, and it is focused on developing deuterium-modified compounds as a means of improving the properties of molecules to produce safer and more effective drugs. They have received several patents for their deuterium chemistry technology.

Overall, Concert Pharmaceuticals Inc. is a promising biopharmaceutical company with a diverse pipeline of drug candidates that have the potential to transform the treatment of several serious diseases. Its focus on deuterium chemistry technology sets it apart from other pharmaceutical companies and provides an innovative solution to improving drug efficacy and safety.


   Company Address: 65 Hayden Avenue Lexington 2421 MA
   Company Phone Number: 860-0045   Stock Exchange / Ticker: NASDAQ CNCE
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Casi Pharmaceuticals Inc

Looking into fourth quarter of 2023 numbers, the Major Pharmaceutical Preparations company's saw a stunning -21.407 %, in revenue

Declining business caused an increase in deficit for the fiscal three months ending December 31 2023, Casi Pharmaceuticals Inc s' deficit per share inched up to $-2.02 from $-3.01 where Revenue went down by -21.407 % to $33.88 million from $43.11 million a year ago.

Neurobo Pharmaceuticals Inc

Neurobo Pharmaceuticals Inc Surprises Investors with Strong Fiscal Fourth Quarter Earnings

he midst of a challenging October to December 2023 reporting season, Neurobo Pharmaceuticals Inc (NRBO) has managed to deliver some encouraging news to investors. Despite expectations of no adjustments at the top-line, the company's operating loss for this period amounted to $-5.667 million. While this figure might raise concerns under different circumstances, it signifies a significant improvement compared to the corresponding period the previous year, which reported an operating loss of $-10.43 million.
This positive development at Neurobo Pharmaceuticals Inc, a major player in the field of Pharmaceutical Preparations, has instilled confidence in market observers. The company's ability to reduce its deficit per share from $-43.44 in the preceding fiscal year to $-2.46, represents a remarkable turnaround. Additionally, Neurobo Pharmaceuticals Inc recorded revenue of $0.00 million for the fiscal 12 Months 2023, a small indication of their ongoing efforts towards establishing prosperous revenue streams.

Agile Therapeutics Inc

Agile Therapeutics Inc. Faces Financial Struggles Amidst Declining Sales Performance

Agile Therapeutics Inc. is a major pharmaceutical preparations company that has recently reported a shortfall in its financial results for the fiscal span of October to December 31, 2023. The company posted a per-stock shortfall of $-1.49 per share, compared to $0.44 per share in the previous year, indicating a significant decline. Additionally, this shortfall represents a decline from the prior financial reporting period, where the per-share shortfall was $-0.27.
Another concerning aspect of Agile Therapeutics Inc.'s financial performance is the substantial decrease in revenue. The company's revenue receded by -14.368% to $3.42 million from $4.00 million in the comparable financial reporting period a year prior. Furthermore, the revenue also tumbled by -44.689% sequentially from $6.19 million. These figures point to a significant decline in the company's financial health.

Tenax Therapeutics Inc

Among many companies, the TENX published also the fourth quarter of 2023 performance

The shareholders have not expected some adjustments at the top-line during the the earnings cycle of fiscal October to December 31 2023 at the Tenax Therapeutics Inc . Yet, they observe the Major Pharmaceutical Preparations company's operating surplus that came in at $3.340937 million, during the matching time.

Sunshine Biopharma Inc

Fascinating conduct by the Major Pharmaceutical Preparations company in the most recent fiscal period

For the most recent fiscal period Sunshine Biopharma Inc reached balanced books of $0.00 per share compare to $-1.31 a year before and from $0.04 per share from the prior reporting season. The revenue inched up strongly by 91.425 % to $7.68 million from $4.01 million in the same reporting season a year before and sequentially revenue improved by 28.913 % from $5.96 million.






 

Concert Pharmaceuticals Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com